专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130344357A1 SOLID BATTERY AND METHOD FOR MANUFACTURING SOLID BATTERY 有权
标题翻译：固体电池和制造固体电池的方法
公开(公告)号：US20130344357A1
公开(公告)日：2013-12-26
申请号：US14003017
申请日：2011-03-17
申请人： Hideaki Miyake
发明人： Hideaki Miyake
IPC分类号： H01M2/12
CPC分类号： H01M2/12 , H01M2/0267 , H01M2/08 , H01M2/14 , H01M6/48 , H01M10/044 , H01M10/0562 , H01M10/0585 , H01M10/34 , Y10T29/4911
摘要： Provided are: a solid battery which has been sealed in an exterior material under a reduced pressure, wherein gas in the exterior material can be fully removed when depressurizing the inside of the exterior material; and a method of manufacturing the solid battery, the solid battery having a single cell having: a laminated body having a cathode layer, an anode layer, and an electrolyte layer disposed between the cathode layer and the anode layer; an insulating part disposed on an outer perimeter of the laminated body in a cross-sectional view of the laminated body in a direction orthogonal to a lamination direction thereof, and a pair of current collectors sandwiching the laminated body and the insulating part, wherein the single cell has been sealed in an exterior material under a reduced pressure; and the insulating part has vent holes.
摘要翻译：提供：在减压下密封在外部材料中的固体电池，其中当外部材料的内部减压时可以将外部材料中的气体完全去除; 以及固体电池的制造方法，所述固体电池具有单电池，所述单电池具有：设置在所述阴极层和所述阳极层之间的具有阴极层，阳极层和电解质层的层叠体; 在层叠体的与其层叠方向正交的方向的截面图中设置在层叠体的外周的绝缘部，以及夹着层叠体和绝缘部的一对集电体，其中，电池在减压下密封在外部材料中; 绝缘部具有通气孔。

2. 发明申请

US20090258089A1 Chemo- and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides 有权
标题翻译：反义TRPM-2寡脱氧核苷酸对癌症的化学和辐射敏化
公开(公告)号：US20090258089A1
公开(公告)日：2009-10-15
申请号：US12431997
申请日：2009-04-29
申请人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson , Tobias Zellweger
发明人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson , Tobias Zellweger
IPC分类号： A61K31/7088 , A61P35/00 , A61K33/24
CPC分类号： A61K31/7125 , A61K31/00 , A61K31/337 , A61K31/66 , A61K31/704 , A61K45/06 , A61K48/00 , C07K14/775 , A61K2300/00
摘要： Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
摘要翻译：针对睾丸激素抑制前列腺消息-2（TRPM-2）基因的反义寡脱氧核苷酸（ODN）的施用可以减少肾细胞癌（RCC）细胞和其他癌细胞中TRPM-2的量，从而增强化学敏感性的这些细胞对化疗药物和辐射。因此，例如，可以通过将肾细胞癌细胞暴露于化疗剂和减少肾细胞癌细胞中TRPM-2的量的试剂来增加肾细胞癌细胞对化疗剂的敏感性。这提供了治疗肾细胞癌的改进方法，其通常对已知化疗剂的治疗具有抗性。

3. 发明授权

US07592323B1 TRPM-2 antisense therapy 失效
公开(公告)号：US07592323B1
公开(公告)日：2009-09-22
申请号：US11276581
申请日：2006-03-06
申请人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson
发明人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson
IPC分类号： A61K31/70 , C07H21/04
CPC分类号： C12N15/1135 , A61K31/00 , A61K31/337 , A61K31/66 , A61K31/704 , A61K41/0038 , A61K45/06 , A61K48/00 , C07H21/00 , C07K14/775 , C12N15/113 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , A61K2300/00 , C12N2310/3525
摘要： It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Thus, prostate cancer can be treated in an individual suffering from prostate cancer by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed.

4. 发明授权

US07491816B2 Antisense therapy for hormone-regulated tumors 有权
标题翻译：激素调节性肿瘤的反义疗法
公开(公告)号：US07491816B2
公开(公告)日：2009-02-17
申请号：US11849845
申请日：2007-09-04
申请人： Gleave Martin , Hideaki Miyake
发明人： Gleave Martin , Hideaki Miyake
IPC分类号： C07H21/04 , A01N43/04 , A61K31/70
CPC分类号： C12Q1/6886 , C12Q2600/106
摘要： A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No. 1), which is derived from the murine gene sequence, and CGCCGTGAGCAACACCAT (Seq. ID. No. 3) and AGGTCATGCACCAGCCGC (Seq. ID No. 4), which are derived from the human gene sequence.
摘要翻译：提供了通过施用与编码IGFBP-5的基因的一部分互补的反义ODN来治疗哺乳动物（包括人）中激素调节的肿瘤（例如乳腺和前列腺肿瘤）的方法。在体外和体内使用Shionogi肿瘤模型，这种ODN的施用显示可以减少肿瘤细胞的增殖，并且也延缓进展到雄激素的独立性。因此，通过向哺乳动物施用治疗有效量的反义寡脱氧核苷酸来完成前列腺癌在包括人类的哺乳动物中的治疗以及前列腺肿瘤的进展延迟到雄激素独立性，所述反义寡核苷酸与编码的核酸序列的一部分互补 IGFBP-5，其与这样的序列杂交以抑制IGFBP-5的表达。适用于该方法的特异性反义ODN's是来自鼠基因序列的GACCACGCTGATCACCAT（Seq.ID.1），和CGCCGTGAGCAACACCAT（Seq.ID.3号）和AGGTCATGCACCAGCCGC（Seq.ID No 4），其源自人基因序列。

5. 发明授权

US07368436B2 TRPM-2 antisense therapy 有权
标题翻译： TRPM-2反义治疗
公开(公告)号：US07368436B2
公开(公告)日：2008-05-06
申请号：US09944326
申请日：2001-08-30
申请人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson
发明人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson
IPC分类号： A61K31/70 , C07H21/04 , C07H21/00
CPC分类号： C12N15/1135 , A61K31/00 , A61K31/337 , A61K31/66 , A61K31/704 , A61K41/0038 , A61K45/06 , A61K48/00 , C07H21/00 , C07K14/775 , C12N15/113 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , A61K2300/00 , C12N2310/3525
摘要： It has been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer, particularly prostate and renal cell cancers. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence, thus prostate cancer can be treated by initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in an individual, and administering a composition effective to inhibit expression of TRPM-2 by the tumor cells. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer and in human Renal cell cancer. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed.
摘要翻译：已经确定减少TRPM-2表达的反义治疗在治疗癌症，特别是前列腺和肾细胞癌方面提供了治疗益处。反义TRPM-2 ODN在体内对前列腺肿瘤细胞的添加对于延缓雄激素独立性的发作是有效的，因此前列腺癌可以通过引发雄激素停药来诱导个体中前列腺肿瘤细胞的凋亡性细胞死亡，并施用有效抑制肿瘤细胞表达TRPM-2的组合物。结合使用反义TRPM-2和紫杉烷类物质协同增强雄激素非依赖性前列腺癌和人类肾细胞癌的细胞毒性化学敏感性。当用反义TRPM-2 ODN处理表达TRPM-2的细胞时，辐射敏感性也增强。因此，反义TRPM-2 ODN可用于增强已观察到TRPM-2表达的各种癌症类型的激素敏感性，化学敏感性和辐射敏感性。

6. 发明授权

US07297684B1 Antisense therapy for hormone-regulated tumors 有权
标题翻译：激素调节性肿瘤的反义疗法
公开(公告)号：US07297684B1
公开(公告)日：2007-11-20
申请号：US09619908
申请日：2000-07-19
申请人： Martin Gleave , Hideaki Miyake
发明人： Martin Gleave , Hideaki Miyake
IPC分类号： A01N43/04 , A61K31/70 , C07H21/04 , C12Q1/68 , C12N5/00
CPC分类号： C12N15/113 , A61K38/00 , C12N2310/315 , C12Q1/6886 , C12Q2600/106
摘要： A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-5 and which hybridizes with such a sequence to inhibit expression of IGFBP-5. Specific antisense ODN's which are suitable for use in the method are GACCACGCTGATCACCAT (Seq. ID. No. 1), which is derived from the murine gene sequence, and CGCGGTGAGCAACACCAT (Seq. ID. No. 3) and AGGTCATGCAGCAGCCGC (Seq. ID No 4), which are derived from the human gene sequence.
摘要翻译：提供了通过施用与编码IGFBP-5的基因的一部分互补的反义ODN来治疗哺乳动物（包括人）中激素调节的肿瘤（例如乳腺和前列腺肿瘤）的方法。在体外和体内使用Shionogi肿瘤模型，这种ODN的施用显示可以减少肿瘤细胞的增殖，并且也延缓进展到雄激素的独立性。因此，通过向哺乳动物施用治疗有效量的反义寡脱氧核苷酸来完成前列腺癌在包括人类的哺乳动物中的治疗以及前列腺肿瘤的进展延迟到雄激素独立性，所述反义寡核苷酸与编码的核酸序列的一部分互补 IGFBP-5，其与这样的序列杂交以抑制IGFBP-5的表达。适用于该方法的特异性反义ODN可以衍生自鼠基因序列的GACCACGCTGATCACCAT（Seq.ID.1号）和CGCGGTGAGCAACACCAT（Seq.ID.3号）和AGGTCATGCAGCAGCCGC（Seq.ID No 4），其源自人基因序列。

7. 发明授权

US5617788A Switching type continuously operative printing machine 失效
标题翻译：开关式连续打印机
公开(公告)号：US5617788A
公开(公告)日：1997-04-08
申请号：US635005
申请日：1996-04-19
申请人： Takeshi Horiguchi , Satoru Sasaki , Hideaki Miyake
发明人： Takeshi Horiguchi , Satoru Sasaki , Hideaki Miyake
IPC分类号： B41F13/00 , B41F7/12 , B41F33/00 , B41F33/04 , B41F33/08 , B41F5/06 , B41F13/12
CPC分类号： B41F7/12 , B41P2213/252 , B41P2217/13
摘要： A continuously operative printing machine and a method of operating the same are disclosed. The printing machine has a plurality of switchable printing units to be used selectively by switching. For continuous printing the printing units are switched alternately by coupling and decoupling first coupling/decoupling means while a continuous printing web is held running. Plate change of stationary printing units is done with independent drive means to be ready for the next printing. Then the stationary printing units are restored to the printing state through synchronous control by rotational control means. Thus plate change printing or the like can be carried out continuously without stopping the printing machine. In addition, high quality printing can be obtained efficiently. Further, it is possible to obtain double side printing.
摘要翻译：公开了连续操作的印刷机及其操作方法。印刷机具有通过切换选择性地使用的多个可切换打印单元。为了连续打印，打印单元交替地通过耦合和去耦合第一耦合/去耦装置，同时连续打印幅片保持运行。固定式印刷装置的印版更换采用独立的驱动装置进行下一次印刷。然后通过旋转控制装置的同步控制将固定打印单元恢复到打印状态。因此，可以在不停止印刷机的情况下连续进行印版变印等。此外，可以有效地获得高质量的印刷。此外，可以获得双面印刷。

8. 发明授权

US08361981B2 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides 有权
公开(公告)号：US08361981B2
公开(公告)日：2013-01-29
申请号：US12431997
申请日：2009-04-29
申请人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson , Tobias Zellweger
发明人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson , Tobias Zellweger
IPC分类号： A61K31/70 , C07H21/04
CPC分类号： A61K31/7125 , A61K31/00 , A61K31/337 , A61K31/66 , A61K31/704 , A61K45/06 , A61K48/00 , C07K14/775 , A61K2300/00
摘要： Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.

9. 发明申请

US20140100261A1 TRPM-2 ANTISENSE THERAPY 有权
标题翻译： TRPM-2抗体治疗
公开(公告)号：US20140100261A1
公开(公告)日：2014-04-10
申请号：US14027693
申请日：2013-09-16
申请人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson
发明人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Nelson
IPC分类号： C12N15/113 , A61K31/337
CPC分类号： C12N15/1135 , A61K31/00 , A61K31/337 , A61K31/66 , A61K31/704 , A61K41/0038 , A61K45/06 , A61K48/00 , C07H21/00 , C07K14/775 , C12N15/113 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , A61K2300/00 , C12N2310/3525
摘要： A method for treating an individual suffering from a cancer comprising administering to the individual a chemotherapeutic agent, and ii) one antisense oligonucleotide having nucleotides in the sequence set forth in Seq. ID No. 4 and which antisense oligonucleotide has a phosphorothioate modification that increases the stability thereof in vivo, wherein the cancer expresses testosterone-repressed prostate message-2 (TRPM-2), thereby treating said individual.
摘要翻译：一种用于治疗患有癌症的个体的方法，包括向所述个体施用化学治疗剂，和ii）一种具有Seq。所述序列中具有核苷酸的反义寡核苷酸。 ID No.4，反义寡核苷酸具有增加其在体内的稳定性的硫代磷酸酯修饰，其中癌症表达睾丸激素抑制前列腺消息-2（TRPM-2），从而治疗所述个体。

10. 发明申请

US20120322850A1 TRPM-2 ANTISENSE THERAPY 失效
标题翻译： TRPM-2抗体治疗
公开(公告)号：US20120322850A1
公开(公告)日：2012-12-20
申请号：US13464670
申请日：2012-05-04
申请人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Helson
发明人： Martin Gleave , Paul S. Rennie , Hideaki Miyake , Colleen Helson
IPC分类号： A61K31/713 , A61P35/00
CPC分类号： C12N15/1135 , A61K31/00 , A61K31/337 , A61K31/66 , A61K31/704 , A61K41/0038 , A61K45/06 , A61K48/00 , C07H21/00 , C07K14/775 , C12N15/113 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , A61K2300/00 , C12N2310/3525
摘要： It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence. Combined use of antisense TRPM-2 and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found that antisense TRPM-2 has beneficial effect for other cancer types. Specifically, antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, a normally chemoresistant disease with no active chemotherapeutic agent having an objective response rate higher than 10%. Radiation sensitivity is also enhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN. Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity, chemosensitivity and radiation sensitivity of a variety of cancer types in which expression of TRPM-2 has been observed.
摘要翻译：现在已经确定减少TRPM-2表达的反义治疗在治疗癌症方面提供了治疗益处。反义TRPM-2 ODN在体内向前列腺肿瘤细胞的添加对于延缓雄激素独立性的发生是有效的。结合使用反义TRPM-2和紫杉烷类物质协同增强雄激素依赖性前列腺癌的细胞毒性化学敏感性。此外，还已经发现反义TRPM-2对其他癌症类型具有有益的作用。具体地，反义TRPM-2 ODN增强了人肾细胞癌的化学敏感性，这是一种没有活性化学治疗剂的客观反应率高于10％的正常化疗耐药性疾病。当用反义TRPM-2 ODN处理表达TRPM-2的细胞时，放射敏感性也增强。因此，反义TRPM-2 ODN可用于增强已经观察到TRPM-2表达的各种癌症类型的激素敏感性，化学敏感性和辐射敏感性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式